Filtered By:
Management: National Institutes of Health (NIH)
This page shows you your search results in order of date. This is page number 11.
Order by Relevance | Date
Total 769 results found since Jan 2013.
Mind the gap from research laboratory to clinic: Challenges and opportunities for next-generation assays in human diseases
Vaccine. 2021 Aug 5:S0264-410X(21)00964-6. doi: 10.1016/j.vaccine.2021.07.071. Online ahead of print.ABSTRACTModern vaccinology has experienced major conceptual and technological advances over the past 30 years. These include atomic-level structures driving immunogen design, new vaccine delivery methods, powerful adjuvants, and novel animal models. In addition, utilizing advanced assays to learn how the immune system senses a pathogen and orchestrates protective immunity has been critical in the design of effective vaccines and therapeutics. The National Institute of Allergy and Infectious Diseases of the National Institut...
Source: Vaccine - August 9, 2021 Category: Allergy & Immunology Authors: M Patricia D'Souza Amy C Palin Thomas Calder Hana Golding Steven H Kleinstein Erin L Milliken David O'Connor Georgia Tomaras Jon Warren Cesar Boggiano Source Type: research
What You Need to Know About COVID-19 Booster Shots
Since the U.S. began a massive country-wide vaccination effort against COVID-19 last winter, a majority of adult Americans have been immunized. But now it seems that all of them may need an additional dose next year.
Public health experts including Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, stress that studies continue to show that the three vaccines currently authorized in the U.S. protect against COVID-19 disease, including against variants of the virus that are more transmissible. But as effective as the vaccines are, they can’t provide 100% immunity against disease. ...
Source: TIME: Health - July 15, 2021 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 Source Type: news
Positive New Data for Johnson & Johnson Single-Shot COVID-19 Vaccine on Activity Against Delta Variant and Long-lasting Durability of Response
NEW BRUNSWICK, N.J., July 1, 2021 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced data that demonstrated its single-shot COVID-19 vaccine generated strong, persistent activity against the rapidly spreading Delta variant and other highly prevalent SARS-CoV-2 viral variants. In addition, the data showed that the durability of the immune response lasted through at least eight months, the length of time evaluated to date. The two preprint study summaries have been submitted today to bioRxiv. “Today’s newly announced studies reinforce the ability of the Johnson & Johnson COVID-19 vaccine to help prot...
Source: Johnson and Johnson - July 1, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news
Adjuvant developed with NIH funding enhances efficacy of India's COVID-19 vaccine
(NIH/National Institute of Allergy and Infectious Diseases) An adjuvant developed with funding from the National Institutes of Health has contributed to the success of the highly efficacious COVAXIN COVID-19 vaccine, which roughly 25 million people have received to date in India and elsewhere. Adjuvants are substances formulated as part of a vaccine to boost immune responses and enhance a vaccine's effectiveness. COVAXIN was developed and is manufactured in India, which is currently suffering a devastating health crisis due to COVID-19.
Source: EurekAlert! - Infectious and Emerging Diseases - June 29, 2021 Category: Infectious Diseases Source Type: news
NIH scientists describe 'multi-kingdom dialogue' between internal, external microbiota
(NIH/National Institute of Allergy and Infectious Diseases) National Institutes of Health scientists and their collaborators have identified an internal communication network in mammals that may regulate tissue repair and inflammation, providing new insights on how diseases such as obesity and inflammatory skin disorders develop. The new research is published in Cell.
Source: EurekAlert! - Infectious and Emerging Diseases - June 23, 2021 Category: Infectious Diseases Source Type: news
Challenges and Strategies in the Development of Radiation Biodosimetry Tests for Patient Management
This article describes various programs and coordinating efforts between NIAID, BARDA and FDA in the development of radiation biodosimetry approaches to respond to radiological and nuclear threats.PMID:34143223 | DOI:10.1667/RADE-21-00072.1
Source: Radiation Research - June 18, 2021 Category: Physics Authors: Merriline Satyamitra Francisca E Reyes Turcu Norberto Pantoja-Galicia Lynne Wathen Source Type: research
The U.S. Government Placed a Big Bet on an Antiviral Pill to Fight COVID-19
We’re not going to vaccinate our way completely out of this pandemic. With epidemiologists around the world increasingly accepting the reality that SARS-CoV-2 and its variants will become endemic viruses—like the seasonal flu—the push is on to develop antiviral medications that can be taken at home to prevent infections from leading to hospitalization and death. Today, the Department of Health and Human Services announced that the Biden Administration has authorized $3.2 billion to accelerate the development of antivirals already in the R&D pipeline, with the hope that at least one will be ready for r...
Source: TIME: Health - June 17, 2021 Category: Consumer Health News Authors: Jeffrey Kluger Tags: Uncategorized COVID-19 Source Type: news
We Used to Have a Lyme Disease Vaccine. Are We Ready to Bring One Back?
At my animal hospital in upstate New York, an epicenter of the U.S. tick epidemic, my dog Fawn lets out a whimper as the veterinarian injects her with her annual Lyme disease shot. I roll my eyes. She doesn’t know how good she has it.
The injection means that if a tick bites her (and in rural New York, a tick always does), the creepy crawly will feast on dog blood that’s been supercharged with a Lyme bacteria-killing substance, and Lyme disease won’t be transmitted to Fawn.
I wish I could be shot up with that superpower. Currently, there is no human vaccine for Lyme disease—even though more than two...
Source: TIME: Health - June 17, 2021 Category: Consumer Health News Authors: Mandy Oaklander Tags: Uncategorized Disease feature Source Type: news
Clinical Trial Evaluating Mixed COVID-19 Vaccine Schedules Begins
(NIH/National Institute of Allergy and Infectious Diseases) The National Institutes of Health has started a Phase 1/2 clinical trial in which adult volunteers who have been fully vaccinated against COVID-19 will receive booster doses of different COVID-19 vaccines to determine the safety and immunogenicity of mixed boosted regimens. The National Institute of Allergy and Infectious Diseases (NIAID), part of NIH, is leading and funding the study through the Infectious Diseases Clinical Research Consortium, a clinical trials network.
Source: EurekAlert! - Infectious and Emerging Diseases - June 1, 2021 Category: Infectious Diseases Source Type: news
NIH scientists find that salmonella use intestinal epithelial cells to colonize the gut
(NIH/National Institute of Allergy and Infectious Diseases) The immune system's attempt to eliminate Salmonella bacteria from the gastrointestinal (GI) tract instead facilitates colonization of the intestinal tract and fecal shedding, according to National Institutes of Health scientists. The study, published in Cell Host& Microbe, was conducted by National Institute of Allergy and Infectious Diseases (NIAID) scientists at Rocky Mountain Laboratories in Hamilton, Montana.
Source: EurekAlert! - Medicine and Health - May 26, 2021 Category: International Medicine & Public Health Source Type: news
Johnson & Johnson Joins World Health Organization in Efforts to Prevent Spread of Ebola in West Africa
Discussions are ongoing with the U.S. Food and Drug Administration regarding the approval of the vaccine regimen in the U.S. WHO Prequalification is often a prerequisite for national registrations of new vaccines and medicines in developing countries. Johnson & Johnson now looks forward to collaborating with the WHO’s African Vaccine Regulatory Forum (AVAREF) to progress national registrations of the Company’s Ebola vaccine regimen. The Company’s Ebola vaccine regimen is designed to be used proactively to induce immunity against Ebola virus disease in adults and children. Johnson & Johnson’s Commitment to E...
Source: Johnson and Johnson - May 13, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news
